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Abstract
Background: The Lufwanyama Neonatal Survival Project (‘‘LUNESP’’) was a cluster randomized, controlled trial that showed
that training traditional birth attendants (TBAs) to perform interventions targeting birth asphyxia, hypothermia, and
neonatal sepsis reduced all-cause neonatal mortality by 45%. This companion analysis was undertaken to analyze
intervention costs and cost-effectiveness, and factors that might improve cost-effectiveness.
Methods and Findings: We calculated LUNESP’s financial and economic costs and the economic cost of implementation for
a forecasted ten-year program (2011–2020). In each case, we calculated the incremental cost per death avoided and
disability-adjusted life years (DALYs) averted in real 2011 US dollars. The forecasted 10-year program analysis included a
base case as well as ‘conservative’ and ‘optimistic’ scenarios. Uncertainty was characterized using one-way sensitivity
analyses and a multivariate probabilistic sensitivity analysis. The estimated financial and economic costs of LUNESP were
$118,574 and $127,756, respectively, or $49,469 and $53,550 per year. Fixed costs accounted for nearly 90% of total costs.
For the 10-year program, discounted total and annual program costs were $256,455 and $26,834 respectively; for the base
case, optimistic, and conservative scenarios, the estimated cost per death avoided was $1,866, $591, and $3,024, and cost
per DALY averted was $74, $24, and $120, respectively. Outcomes were robust to variations in local costs, but sensitive to
variations in intervention effect size, number of births attended by TBAs, and the extent of foreign consultants’
participation.
Conclusions: Based on established guidelines, the strategy of using trained TBAs to reduce neonatal mortality was ‘highly
cost effective’. We strongly recommend consideration of this approach for other remote rural populations with limited
access to health care.
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Introduction
In many low-resource countries, neonatal mortality contributes
approximately 40% of all under five-year mortality, with birth
asphyxia and neonatal sepsis constituting the majority of
preventable neonatal deaths [1,2]. A major factor in high neonatal
mortality is the high proportion of home births. It is estimated that
60 million deliveries occur each year outside of health facilities [3];
in many low-resource areas over 50% of all births occur in the
community, largely in mothers’ homes [4]. In many areas,
traditional birth attendants (TBAs) are an essential source of basic
obstetrical care. TBAs have proven effective in a variety of
secondary roles in the community, such as serving as peer
educators or breast feeding counselors, but their proximity to the
mother/infant pair and their location within the community
suggests that TBAs could play a more direct role in reducing
neonatal deaths as well.
To test the hypothesis that TBAs could effectively reduce
neonatal mortality in a rural African setting, we conducted a
randomized controlled effectiveness study in Zambia called the
Lufwanyama Neonatal Survival Project (LUNESP) [5]. In
LUNESP, TBAs were randomized to receive training and
equipment to allow them to perform a set of interventions
targeting several of the main causes of neonatal mortality. The
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Protocol (NRP), which aimed to reduce deaths due to birth
asphyxia and hypothermia; and 2) antibiotics with facilitated
referral to a health center (AFR), which aimed to reduce sepsis
deaths during the first month of life. The primary endpoint was a
comparison of mortality rates by day 28 of life among live-born
infants. Based on outcomes for 3355 deliveries, we found that
infants delivered by intervention TBAs were 45% less likely to die
than infants delivered by control TBAs (RR 0.55, 95% CI 0.33 to
0.90). This equated to one death avoided for every 56 deliveries
attended by an intervention TBA, for an absolute reduction of 18
deaths per 1000 live births [5].
Here we report on the economic evaluation component of the
LUNESP project. We present our findings from several perspec-
tives. First, we present a financial analysis, based on the actual
costs incurred during the intervention. Second, we present an
economic analysis, which utilized a societal perspective of costs.
Lastly, as evidence for policy-makers, we present a forecasted
economic analysis in which the costs and cost-effectiveness of a
modified model of the intervention are projected over a ten-year
timeframe.
Methods
Study summary
LUNESP was a cluster-randomized trial conducted from 2006–
2008 in an impoverished rural district in north-central Zambia
among a population with limited access to health care [5]. A total
of 120 TBAs were initially randomized to receive the intervention
trainings and equipment, or to continue their existing standard of
care. All TBAs received one ‘clean delivery’ kit per birth for their
regular TBA duties, which included a delivery sheet, cord cutter,
cotton cord ties, latex gloves, and soap. Training for intervention
TBAs commenced with 4-day sessions for each group of 30 TBAs,
followed by 1–2 day refresher trainings approximately every 3–4
months for the duration of the trial. The trainings were conducted
collaboratively by a US-based neonatologist and a local master
trainer (a Zambian nurse-midwife), assisted by 6–8 Zambian
facilitators. To demonstrate competency, intervention TBAs
indicated skills retention at each retraining session. Each
intervention TBA received one resuscitator mask, a polypropylene
bottle with chlorinated water, and a laminated reference card
summarizing NRP and trigger conditions for AFR. They also
received each of the following per delivery: two flannel receiving
blankets, a soft rubber bulb syringe, two 250 mg amoxicillin
capsules, one 2-ounce mixing cup and spoon, and a 3 ml oral
syringe. A more detailed description of the design, training, and
analytic methods used in LUNESP has been published elsewhere
[5].
The study was approved by the ethical committees at Boston
University Medical Center (Boston, MA) and the Tropical
Diseases Research Centre (Ndola, Zambia). All TBAs and mothers
who participated in the LUNESP trial provided written informed
consent, using forms in English and the local languages Bemba
and Lamba. We did not obtain separate informed consent from
participants for the present analysis because we utilized de-
identified, aggregated outcome data only from the trial. The
LUNESP trial was registered as clinicaltrials.gov NCT00518856.
Cost analyses
Analyses were conducted from three perspectives: 1) a financial
analysis based on costs incurred during LUNESP; 2) an economic
analysis, which factored in societal costs; and 3) a forecasted 10-
year economic analysis, which modeled expected intervention
economic costs and effectiveness over a future program-appropri-
ate timeframe in order to provide practical information for policy-
makers beyond data generated by a short-term research study
alone.
Financial analysis. The financial analysis was based on the
incremental expenditures related to the 33-month intervention.
This encompassed 6 months of start-up activities in February–July
2006, including the first training and 27 months of implementation
from August 2006-October 2008) (Table 1). All research- and
control group-related costs were excluded. We included personnel
time for: start-up (US-and Zambia-based collaborators); program
monitoring and supervision (Zambian project staff); project
coordination (Zambian project staff); and training. We included
the costs of travel, food, and accommodation associated with
training. Some travel expenses by the US-based neonatologist
were defrayed due to cost-sharing with other projects; these
savings were incorporated. TBAs were not paid by the
government or the study and thus no salaries were included.
Supply costs included training items (resuscitation mannequins,
printing, and stationary); single items provided to each TBA at the
beginning of the intervention such as a mask, instruction card, and
a mixing spoon; and items needed for each birth, including
blankets and bulb syringes. Some supplies were purchased locally
and others were purchased in the US and brought to Zambia by
project staff. We included a one-time customs charge applied to
supplies carried into Zambia and a shipping fee for items shipped
from the US in 2006. The District Health Management Team
(DHMT) was responsible for providing amoxicillin and clean
delivery kits, though due to occasional supply issues, the program
made several purchases of both items, the costs of which were
included. Nominal Zambia-based costs were converted to US
dollar values using the average annual exchange rate for the year
in which the costs were incurred [6] and then added to nominal
US dollar-based costs. We adjusted total annual US dollar costs by
US inflation rates (Consumer Price Index) [7] and expressed total
program costs in real 2006 US dollar figures, categorized as fixed
and variable costs over the life of the project. We also estimated
the 2006 Present Value (PV) of financial costs (using a discount
rate of 3%) [8], and the 2011 PV for greater comparability with
additional analyses.
Economic analysis. As recommended by the World Health
Organization, we utilized a societal perspective for the economic
analysis to better capture the economic resource cost of
intervention inputs [9]. First, we included payment to TBAs for
their participation. This was based on the supply price of TBAs,
estimated by calculating the difference in reported average cash
payments per birth made by families to intervention TBAs vs.
control TBAs. Second, we eliminated cost-sharing of expenses (i.e.,
subsidized travel of US-based neonatologist, donations of key
supplies). Third, we included the cost of amoxicillin tablets
throughout the project, using an estimated international price of
US$ 0.1 per 250 mg dose (but assumed consistent delivery kits by
the DHMT per their mandate) [10]. Fourth, we deducted the
customs tax payment, since taxes are an economic transfer and not
an actual resource cost. All US dollar nominal costs were adjusted
for US inflation rates [7], discounted at 3%, and expressed in 2011
US dollar PV terms.
Forecasted 10-year analysis. We utilized a societal
perspective, with a ten-year program lifespan from January 2011
through 2020. We assumed a similar model as that of the trial: 6
months of start-up, 60 participating TBAs, initial intensive 4-day
training followed by three 2-day refresher trainings per year, the
same supply inputs, and similar levels of local personnel
participation in training and monitoring and supervision
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localize the intervention and increase its long-term sustainability.
We assumed task-shifting by replacing the US-based neonatologist
with a local skilled nurse-midwife who would have 5 full-time
facilitators for assistance with trainings. We anticipated that TBA
turnover would be minimal over time, with training of new TBAs
managed by including them in ongoing refresher training rather
than holding additional new trainings. US program management
was replaced with a team of 3 local staff who would establish the
intervention over 30 days. We also estimated compensation for
TBAs on the basis of the per birth payments made by families to
intervention TBAs during the trial. All nominal costs included
expected inflation [7,11]; nominal TBA compensation also
incorporated a real annual increase of 1%. We assumed no
improvements in or loss of efficiency over time, resulting in similar
annual costs after the start-up period. Annual Zambia-based costs
in local currency were converted to nominal US dollars using an
expected constant real exchange rate equal to the 2011 rate [6]
and added to annual US dollar costs. Total annual costs were
deflated by expected inflation and discounted (at 3%) to estimate
the 2011 PV.
Cost-effectiveness analyses
We estimated the cost effectiveness of the LUNESP interven-
tions using the formula: ICEA=(CI2CC)/(MI2MC), where ICEA
is the incremental cost-effectiveness ratio; CI and CC are the total
(discounted) costs related to the intervention and control groups,
respectively; and MI2MC are the (discounted) mortality figures for
intervention and control groups, respectively. Because all costs
were incremental, CC=0. The difference in mortality per year,
(MI2MC)t, where t=years 2006, 2007, 2008, was the difference in
measured mortality rates per 1,000 live births between interven-
tion and control groups in each project year. Annual lives saved
were discounted at 3% per year. We also estimated the number of
averted disability-adjusted life years (DALYs), using an approach
that incorporates expected years of life lost (not country-specific),
with time lived at different ages valued using an exponential
function and discounted at 3% [12].
For the forecasted CEA we conducted three analyses. First, our
base case used the estimated economic costs for the 10-year
program and assumed that reduced mortality would equal the
trial’s overall effect size (17.9/1000 births). The number of
expected births per TBA was defined as the annual number
observed in 2008 (when TBA activity was at its peak) (1.29 births
per TBA per month). We estimated both undiscounted and
discounted (at 3%) annual deaths avoided, though used the latter
to calculate the incremental economic cost per death avoided and
DALY averted. In addition, we examined the cost-effectiveness of
two alternative ‘optimistic’ and ‘conservative’ scenarios. The
former retained the trial’s mortality effect and assumed program
implementation under more stringent conditions by increasing the
number of TBAs per cohort trained from 60 to 80, reducing the
refresher training time from 2 to 1 days, reducing monitoring
activities from a monthly to bi-monthly timetable, and assuming
births based on Zambia’s average national density rather than
sparsely-populated Lufwanyama (see Table 2). The conservative
scenario, relative to the base case, involved reducing the effect size
by 25% to 13.4/1000 births, decreasing the mean monthly
number of births per TBA to the overall average observed in the
trial (1.21), and increasing the number of annual refresher
trainings from 3 to 4.
Interpretations regarding ‘cost-effectiveness’ were based on the
2001 recommendation of the Commission on Macroeconomics
and Health and adopted by the World Health Organization
(WHO), whereby an intervention is ‘highly cost-effective’ if it
averts a DALY for less than per capita GDP (Gross Domestic
Product) and ‘cost-effective’ if it averts a DALY for less than 3
times per capita GDP [13].
Sensitivity analyses
For the base case, we conducted univariate sensitivity analyses
to explore the impact on the costs and cost effectiveness of the 10-
year program of varying key input parameters. Certain variables
were uncertain—mortality effects, number of births per TBA, and
input costs. Others were pre-determined, either wholly or in part,
by program or policy staff, including the number of refresher
Table 1. Items included in cost analysis.
Personnel Costs Comments
Personnel costs during start up activities 30 days preparation time each for the US and Zambian teams
Personnel costs for monitoring during the interventions Zambian project director: 2 days/month
Personnel costs for training workshops Zambian TBA trainer: 5 days/month
Training facilitators (6 facilitators)
Project coordinator: 4 days/month
US neonatologist attending trainings: attended 5 of 9 workshops
1
Zambian trainers attended 9 of 9 workshops
Travel, food and lodging for TBAs attending workshops 9 workshops660 intervention TBAs
Supply Costs Comments
Training supplies Infant resuscitation mannequins, printed materials
Intervention supplies – one-time costs (per TBA) Resuscitation mask; polypropylene water bottle used to make slurry with amoxicillin);
medication cup; mixing spoon; laminated card pictorially summarizing steps of NRP
(front) and AFR (back)
Intervention supplies – recurrent costs (per delivery by an intervention TBA) 1 safe delivery kit, 1 bulb syringe, 2 flannel receiving blankets, 2 amoxicillin tablets
(250 mg), oral syringe (for administering amoxicillin/water slurry)
1Some travel expenses of the US-based neonatologist were defrayed due to cost-sharing related to airline tickets and local food and accommodation. In the financial
analysis, costs incorporated these savings.
doi:10.1371/journal.pone.0035560.t001
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degree of involvement of the US-based neonatologist in training
activities, and number of participating TBAs trained per
workshop.
We also conducted multivariate sensitivity analysis with Monte-
Carlo simulations using Crystal Ball
TM (Oracle Corp, Redwood
Shores, CA) to test the model’s robustness for each of the three
forecasted scenarios given simultaneous changes in key parame-
ters, an approach commonly employed in cost-effectiveness
Table 2. Input values for multivariate sensitivity analysis, by scenario.
Parameter
Type of
probability
distribution
1 Minimum Value
2 Likeliest value Maximum Value
2 Sources
Uncertain variables
Mortality effect
Base case Triangular 4.1 17.9 31.8 LUNESP trial
Optimistic scenario Triangular 4.1 17.9 31.8 LUNESP trial
Conservative scenario Triangular 3.1 13.4 23.9 Estimate
3
Births attended per BA/month
Base case Triangular 0.70 1.29 1.87 LUNESP trial
4
Optimistic scenario Triangular 1.82 3.34 4.86 Estimate
5
Conservative scenario Triangular 0.49 1.21 1.93 LUNESP trial
6
Cost of food/day/participant during
training workshops
7
Base case Triangular 10.6 14.1 17.7 LUNESP trial
Optimistic scenario Triangular 10.6 14.1 17.7 LUNESP trial
Conservative scenario Triangular 10.6 14.1 17.7 LUNESP trial
Cost of fuel, car, staff for program
monitoring/month
7
Base case Triangular 466 622 777 LUNESP trial
Optimistic scenario Triangular 466 622 777 LUNESP trial
Conservative scenario Triangular 466 622 777 LUNESP trial
Policy-determined variables
Number of trainings/year
Base case 3 LUNESP trial
Optimistic scenario 2 Estimate
8
Conservative scenario 4 Estimate
8
Number of days/training
Base case 2 LUNESP trial
Optimistic scenario 1 Estimate
8
Conservative scenario 2 LUNESP trial
Months/year of monitoring
Base case 12 LUNESP trial
Optimistic scenario 6 Estimate
8
Conservative scenario 12 LUNESP trial
Number of TBAs
Base case 60 LUNESP trial
Optimistic scenario 80 Estimate
8
Conservative scenario 60 LUNESP trial
1Triangular distribution was chosen to be consistent with the approach used in other cost-effectiveness studies [24–26].
2For parameters except births/TBA, these are minimum and maximum values. For births/TBA, these are 5% and 95% values determined by the 95% CI estimated from
the standard deviation of monthly mean births/TBA from the LUNESP trial.
325% less than the LUNESP trial’s mortality effect. Using a +/225% range is typical in similar studies [17].
4Based on the average number of births attended/TBA/month during the final year of the LUNESP trial.
5Estimated value for typical area in Zambia, calculated by multiplying the LUNESP trial’s mean value by the factor: (Zambia national population density/average
population density in Lufwanyama).
6Based on the average number of births attended/TBA/month during the 27 months of LUNESP trial implementation.
7Costs in estimated 2011 US$.
8Authors’ estimates based on experience during the LUNESP trial.
doi:10.1371/journal.pone.0035560.t002
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analysis for the base case, we selected the four uncertain input
parameters (e.g., non-policy determined) whose variations had the
greatest impact on the cost-effectiveness outcomes to include in
this analysis: intervention effect size, average deliveries/month/
TBA, logistic costs of trainings (e.g., room and board), and cost of
travel for monitoring and supervision. The probability distribu-
tions for input parameters were assumed to be triangular. For the
mortality effect, the likeliest value was taken from the trial, with
minimum and maximum ranges set at the trial’s 95% confidence
interval (CI). For the number of births per TBA, we used the trial
mean and standard deviation to estimate a 95% CI. For 2011 cost
parameters, we used the 2011 estimated costs for likeliest values
with minimum and maximum ranges of 625% (Table 2), an
approach frequently employed in similar cost studies [17].
Results
Intervention costs and cost-effectiveness
In the financial analysis, the program intervention costs in real
2006 US$ were $47,020, $32,599, and $29,282 in 2006, 2007, and
2008, respectively (Table 3). After discounting, the 2006 PV was
$106,271. The cost of start-up and supplies, as well as the longer
training workshop in June 2006, was primarily responsible for the
higher annual costs in 2006 relative to 2007–08. The cost
difference between 2007 and 2008 reflected the fact that the study
was implemented for only 10 months in 2008. Approximately two-
thirds of the cost of the program’s first year was US-based, whereas
in 2007 and 2008, US-based costs represented less than 30% of
total costs. Twenty-seven percent of total financial costs were for
the US-based neonatologist.
LUNESP’s total economic cost was 8% higher than the total
financial cost, mainly due to costs associated with the US-based
neonatologist’s attendance at all workshops (Table 4). Fixed costs
accounted for nearly 90% of economic costs, among which the
largest component was training activities (63–65% of total annual
costs). Thirty-one percent of all economic costs were for the US-
based neonatologist.
In the forecasted analysis, the estimated 2011 PV of the base
case program was $256,455, with annual costs of $26,834, far
lower than in the financial and economic analyses of the 2006–08
intervention, where annual costs were $49,469 and $53,550,
respectively (Table 4). Lower annual cost resulted largely from
spreading out first year start-up costs over a longer timeframe.
Moreover, in contrast with the cost drivers for the 2006–08
program, training for the 10-year program comprised less than
50% of total costs, rather than nearly two-thirds, whereas
monitoring and supervision represented almost one-third of total
costs, or about double the proportion of LUNESP’s costs. These
differences were mainly due to task shifting from the US-based
neonatologist to a local trainer (i.e., the lead Zambian trainer, a
nurse-midwife). Despite savings from these adjustments, fixed costs
were still projected to account for over 80% of total intervention
cost. Task-shifting and compensating TBAs had minimal effect on
the basic cost structure of the program. Given the low prices of
variable cost items—infant receiving blankets, bulb syringes,
amoxicillin tablets, and compensation to TBAs—fixed costs still
far exceeded variable costs. Overall, the model predicted that the
estimated cost per birth would be less than one-half that of
LUNESP’s economic resource cost (US$29 vs. $68). The variable
cost per birth, representing the additional cost of having a trained
TBA attend a delivery, was US$5.3, compared to US$8.4 for the
2006–08 trial.
The cost per neonatal death avoided and DALYs averted for
both the 2006–08 program and the 2011–2020 program are
summarized in Table 5. From the 33 neonatal deaths that were
avoided (undiscounted) in 2006–08, we estimated that 158 deaths
would be avoided in 2011–2020. For the 2006–08 program, the
economic cost per death avoided was $3,900 while the cost per
DALY averted was $176 (2011 US dollars). The 10-year
forecasted program was much more cost-effective than LUNESP.
The base case analysis predicted that the cost per death avoided
was $1,866, while the cost per DALY averted was $74. ‘Optimistic’
vs. ‘conservative’ scenarios yielded values of $591 vs. $3,024 and
$24 vs. $120 for cost per death avoided and DALY averted,
respectively. Given that Zambia’s 2011 GDP per capita was
estimated to be just under $1400 (in current prices) [18], this
analysis suggested that all scenarios of the intervention, including
the conservative scenario, would be highly cost-effective.
Sensitivity analyses
The one-way sensitivity analyses showed that the 10-year base
case results were most sensitive to variation in two policy-
determined variables: the degree of involvement of the US-based
neonatologist and number of program TBAs (Table 6). If the
neonatologist attended all 3 trainings each year instead of none,
the total cost per outcome (death avoided, DALY averted, and
birth attended by TBA) would nearly double. Similarly, if the
trainings expanded to include 100 TBAs per session rather than
60, cost-effectiveness would increase by approximately 20%. The
results were also sensitive to variation in the effect size of the
intervention and productivity of a given TBA (i.e., the average
monthly number of deliveries attended). If the intervention
reduced neonatal mortality by 8.0 (vs. 17.9 in the base case) per
1,000 live births, the cost per death avoided and DALY averted
would increase by over 100%. If the intervention was implement-
ed in an area where TBAs helped deliver more babies, e.g., 5
instead of 1–2 per month, cost-effectiveness would improve by
more than 50%.
The multivariate sensitivity analyses indicated that the results
were robust to simultaneous variation in key input parameters
(Table 7). The forecasted median values of cost per death avoided
and DALY averted, for all scenarios, were within 5–6% of the
point estimates. The 90% probability values were generally less
than twice the point estimates. With 90% probability, the cost per
DALY averted of the base case scenario would be less than $148,
and for the conservative scenario would be less than $276. Thus,
even under very conservative policy-determined conditions and
extreme outcome conditions, the intervention should still be
considered highly cost-effective.
Discussion
This analysis indicted that training TBAs to perform interven-
tions targeting birth asphyxia, hypothermia, and sepsis was highly
cost-effective according to the WHO-accepted definition of cost-
effectiveness. Furthermore, modifications to localize investments
and spread them out over a 10-year program horizon would
significantly enhance the cost effectiveness of the intervention.
Some studies have identified even more cost-effective interventions
to improve child survival in certain settings such as India ($7 per
DALY averted for home-based neonatal care) [19], and in a
number of countries in the same African region as Zambia ($8 per
DALY averted for community newborn care) [20]. However, our
results compare favorably with the range of interventions
presented by the WHO as cost-effective in very low-resource
environments, such as delivery by a skilled birth attendant ($37 per
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neonatal infections ($54 per DALY averted) [20].
Important drivers of our results were the intervention’s effect
size (reduced mortality) and high fixed costs. The latter was related
to the nature of the intervention, which requires substantial
training and retraining over time. However, as the sensitivity
analysis and 10-year model illustrate, there are ways to task-shift
and adapt the training to dramatically reduce some of these costs.
By contrast, the former was entirely a function of the local
population structure and the low average number of deliveries the
Table 3. Summary of the financial costs of the LUNESP intervention: 2006–08.
Parameters 2006 2007 2008
Number of months of intervention set-up 6
Number of months of intervention implementation 5 12 10
A. Zambia in-country costs (US$)
1
Personnel salaries
Program set-up and monitoring 3129 11321 9434
Training: trainers/facilitators 3442 9794 8978
Food & accommodation (trainings)
Trainers/facilitators 919 7414 7626
TBAs
2 3597 20269 20032
Travel
Program set-up and monitoring 1123 19013 22217
TBAs: trainings
2 3450 19160 10261
Supplies
Infant receiving blankets 1406 11500 5000
Amoxicillin 107 80 0
Clean delivery kits 01 5 4 2 5 4 6
Printing & stationary – trainings 267 1139 2891
Miscellaneous
Customs clearance charge 281
Total Zambia in-country costs 17721 24608 22785
B. US-based costs (US$)
Personnel salaries
Program set-up and monitoring 4961 0 0
Training: Neonatologist 9244 6409 2499
Food & Accommodation (trainings)
Neonatologist 001 3 2
Travel (US-Zambia for trainings)
Neonatologist 4370 2511 4441
Supplies
Infant receiving blankets 1426 0 0
Laederal resuscitation masks 1095 0 0
Resuscibaby manikins 2125 0 0
Laminated instruction cards 112 0 0
Bulb syringes 4320 0 1190
Plastic spoons 65 0 0
Miscellaneous
Shipping: supplies to Zambia 1583
Total US-based costs 29299 8920 8488
Total US-based & Zambia in-country costs 47020 33528 31273
Total Costs: Real 2006 US$ 47020 32599 29282
Present Value: 2006 US$
3 $106271
1In-country costs were converted to US dollar values at the following average annual ZMK/US$ exchange rates: 3557 (2006), 4114 (2007), and 3818 (2008) [6].
260 TBAs.
3Discount rate=3%.
doi:10.1371/journal.pone.0035560.t003
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population density (,6.4 persons/kilometer, roughly one third of
Zambia’s average [21]). Thus, the greatest economies are likely to
be achieved when TBAs have the opportunity to apply their skills
more frequently. In this regard, LUNESP’s cost-effectiveness
might underestimate the cost-effectiveness that could be achieved
in a more densely populated setting.
Strengths and weaknesses
The prospective collection of cost data during the course of an
actual field study, rather than estimating costs, is an important
strength of the study. Similarly, the intervention’s effect size was
measured directly from a methodologically-rigorous randomized
controlled trial, rather than from assumptions or expert opinion.
Both of these enhance the validity of our findings. The forecasted
economic analysis takes the analysis one step further, creating
several potential scenarios of how an intervention of this kind,
conducted in a similar population but over a 10-year time scale,
might perform programmatically. In addition, our sensitivity
analysis identified several policy- or program-determined variables
that could substantially reduce costs and increase sustainability.
This provides useful information for policy makers interested in
achieving the maximum yield for public health investments.
Several potential limitations of the 10-year projected interven-
tion merit discussion. First, our results are derived from one
particular setting. While they may be generalizable to similar
contexts characterized by low population density and underde-
veloped transportation and health systems where home births are
often the only option, the precise degree to which the efficiencies
we achieved in the 10-year program can be gained in other
settings is uncertain. For example, the LUNESP TBAs were highly
motivated, largely because of their participation in a foreign-
managed project. Whether TBAs participating in a completely
locally-run program would be equally eager and conscientious in
applying their skills is impossible to predict. However, it could also
be argued that the Lufwanyama context represented a relatively
extreme situation in terms of the difficulties of introducing an
intervention of this kind. The LUNESP TBAs served a vast
geographic area, which made it more difficult for them to access
their clients and increased the logistical complexity and costs
associated with training workshops and program monitoring. The
TBAs’ educational levels were also low; 17% had never attended
school and only 13% had progressed beyond primary school [5].
Moreover, as mentioned above, LUNESP’s TBAs attended
relatively few deliveries (an average of 1.2 each month), which
had an adverse impact on the intervention’s impact and hence
lowered cost-effectiveness.
Table 4. Fixed and variable costs of the LUNESP interventions (2011 US$)
1
Cost item Financial Economic Projected Economic
2006–08 2006–08 2011–20
Cost % total Cost % total Cost % total
Total fixed costs
2 104514 88.1 111902 87.6 208306 81.2
Program set-up 7268 6.1 7268 5.7 1531 0.6
Monitoring & supervision 19256 16.2 19256 15.1 83092 32.0
Training workshops 74806 63.1 82507 64.6 120063 46.8
Foreign personnel
3 31771 26.8 39473 30.9 - 0.0
Local personnel
4 11036 9.3 11036 8.6 28686 11.2
TBAs
5 25773 21.7 25773 20.2 85079 33.2
Supplies
6 3706 3.1 3706 2.9 6298 2.5
Supplies (non-training)
7 1418 1.2 1418 1.1 2185 0.9
Total variable costs
2 14060 11.9 15854 12.4 48149 18.8
Supplies
8 14060 11.9 14353 11.2 32150 12.5
TBA compensation
9 - 0.0 1501 1.2 16000 6.2
Total costs 118574 100.0 127756 100.0 256455 100.0
Cost per program year
10 49469 53550 26834
Cost per birth
11 62.8 67.6 29.1
Variable costs per birth 7.4 8.4 5.3
1All figures are in discounted (at 3%) real 2011 US$.
2Fixed costs include program set-up, monitoring, training, and supplies provided to TBAs on a per-TBA basis; variable costs include supplies provided on a per birth
basis and compensation toTBAs), since these are estimated based on average deliveries/month.
3Participation of one US-based neonatologist in training workshops, including time spent (salary), travel, and in-country food/accommodation.
42006–08 intervention: assistant trainer, program director, local supervisor, and 4 additional full-time facilitators during trainings. 2011–2020 intervention: lead trainer
(nurse midwife) and five facilitators.
560 TBAs.
6Training supplies included resuscitation mannequins and printed materials.
7Additional non-training supplies included in fixed costs were all supplies provided to TBAs on a per-TBA basis: instruction cards, Laederal resuscitation masks, and
plastic spoons.
8Supply costs included among variable costs were: infant receiving blankets, bulb syringes, and amoxicillin tablets.
9Estimated on a per-birth basis.
10Annualized for program implementation period only (i.e., excluding set-up period but including initial training).
11Cost per birth attended by intervention TBAs in 2006–08 program (1889) and estimated for 2011–2020 projected period (9120).
doi:10.1371/journal.pone.0035560.t004
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such as the retraining frequency and the number of TBAs per
training. In reality, there are limits to the changes in training one
can make without decreasing intervention effectiveness. In support
of this, Carlo et al, working with an unrelated group of Zambian
TBAs, observed significant attrition of skills when TBAs were
reassessed six months after primary training [22]. Therefore,
making such changes would require a monitoring strategy to
ensure that essential skills are acquired and retained. However, it is
important to bear in mind that in sparsely-populated areas such as
Lufwanyama, where TBAs average 1–2 deliveries monthly, skill
retention is likely poorer than in settings where TBAs can attend
closer to 5–6 deliveries per month. In more populous areas, the
increased utilization of skills could be self-reinforcing and thus
permit fewer refresher workshops. This emphasizes the need to
assess TBAs’ skills regularly and systematically in order to optimize
retraining efforts.
Third, our results assume that task shifting from expensive and
experienced US-based experts to local experts paid at local wages
will not compromise the intervention’s effectiveness. We consider
this a reasonable assumption: neonatal resuscitation is not
technically complex to teach or to perform, and should not
require the very high expertise of tertiary care center neonatol-
ogist. In other settings, training skills have been transferred
successfully to local trained staff such as mid-wives [23].
Fourth, we lacked the data to incorporate the treatment of
conditions for children who survived due to the work of the TBAs
(additional costs) as well as the treatment of perinatal complica-
tions which were averted by the involvement of the TBAs (cost
savings). The incorporation of such additional potential costs and
savings would inevitably strengthen our analyses.
Finally, in our forecasted model, we used a simple, linear
progression of costs over time after making initial baseline cost
assumptions for year 1 (2011), rather than employing more
sophisticated techniques, including non-linear cost projections.
However, handling the inherent uncertainty of future values with
sensitivity analysis encompassing a range of scenarios and a Monte
Carlo simulation analysis is a rigorous approach that is intuitive
and transparent. In addition, a rigorous cost-effectiveness analysis
of a nationwide version of the intervention might provide even
more relevant information for policy-makers. Yet given the
variation in so many key parameters that such an analysis would
need to encompass, and our lack of reliable data on these varying
parameters, we do not believe such an analysis would produce
reliable results. We hope instead that our rigorous analysis of a
modestly-sized program, based as it is on trial-generated data with
Table 5. Program cost-effectiveness: 2006–08 and 2011–20.
Neonatal deaths avoided
Neonatal deaths avoided, 2006–08 (undiscounted) 33.1
Neonatal deaths avoided, 2006–08 (discounted @ 3%) 32.8
Neonatal deaths avoided, 2011–20 (undiscounted) 157.6
Neonatal deaths avoided, 2011–20 (discounted @ 3%) 137.4
DALYs averted
1
DALYs averted, 2006–08 725
DALYs averted, 2011–20 3,451
Cost per neonatal death avoided
2
Financial cost per death avoided, 2006–08 3620
Economic cost per death avoided, 2006–08 3900
Estimated economic cost per death avoided, 2011–2020
Base case 1866
Optimistic scenario 591
Conservative scenario 3024
Cost per DALY averted
2
Financial cost per DALY averted, 2006–08 163
Economic cost per DALY averted, 2006–08 176
Estimated economic cost per DALY averted, 2011–2020
Base case 74
Optimistic scenario 24
Conservative scenario 120
1Death of a neonate=21.9 DALYs averted, estimated by the formula given by
Murray, 1994.
2All costs expressed in real 2011 US$, with annual values discounted at 3%.
doi:10.1371/journal.pone.0035560.t005
Table 6. Results of one-way sensitivity analysis on the incremental cost per birth attended, cost per death avoided, and cost per
DALY averted of LUNESP package of neonatal interventions: 2011–2020 program (2011 US$).
Variation tested
Cost per expected birth
attended by TBA
Cost per death
avoided Cost per DALY averted
Base case $29 $1866 $74
Mortality difference (intervention impact) varied between 24/1,000
and 8/1,000 (base case=17.9)
no change $1392–4175 $55–166
Average number of births/month/TBA varied between 5 and 1
(base case=1.3)
$12–36 $740–2301 $30–92
Number of participating TBAs varied between 100 and 40 (base case=60) $24–36 1521–2298 $61–92
Number of training workshops varied between 1 and 3 per year
(base case=3 per year)
$20–29 $1288–1866 $51–74
Number of training workshops attended by US expert varied
between 0 and 3 per year (base case=0 per year)
$29–52 $1866–3314 $74–132
Cost of food per day/participant at trainings varied +/225%,
between $8.1–13.5 (base case=10.8)
28–31 1768–1963 70–78
Cost of travel per month for program monitoring varied +/225%,
between $356–593 (base case=74)
27–31 1753–1978 70–79
doi:10.1371/journal.pone.0035560.t006
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35560transparent modifications and a careful examination of uncertain
variables, can be used for programmatic purposes in settings
similar to that of LUNESP.
Conclusion and policy implications
This analysis indicates that training TBAs in practical skills
targeting the key causes of neonatal mortality is highly cost-
effective. Moreover, it shows that the cost-effectiveness of this
strategy can likely be improved if implemented programmatically
over a longer time horizon and with deliberate cost-saving
measures. These results further strengthen the rationale for
implementing programs similar to LUNESP in other disadvan-
taged communities with extremely limited access to health care.
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